| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5692495 | The Breast | 2017 | 7 Pages |
Abstract
The EVA study provided new insights in the use of EVE-EVE combination in HR+Â ABC pts many years after the publication of the pivotal trial. The combination is safe and the best response could be obtained in patients receiving the full dose of EVE and/or after hormone-therapy as Fulvestrant in ABC.
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
M.E. Cazzaniga, M. Airoldi, V. Arcangeli, S. Artale, F. Atzori, A. Ballerio, G.V. Bianchi, L. Blasi, S. Campidoglio, M. Ciccarese, M.C. Cursano, M. Piezzo, A. Fabi, L. Ferrari, A. Ferzi, C. Ficorella, A. Frassoldati, A. Fumagalli, F. Riva,